津药药业：子公司注射用甲泼尼龙琥珀酸钠获巴拿马注册证书

Core Viewpoint - The company announced that its subsidiary, Tianyao Heping, has received registration certification from the Ministry of Health of the Republic of Panama for its injectable methylprednisolone sodium succinate (500mg freeze-dried powder injection), allowing for local production and sales [1] Group 1: Product Approval and Market Expansion - The approved drug is a corticosteroid used for anti-inflammatory treatments [1] - The registration application was submitted in 2024, and the certification was obtained in November 2025 [1] - The global sales figures for methylprednisolone injectable products are projected to be $526 million in 2023 and $521 million in 2024 [1] Group 2: Strategic Implications - This approval presents an opportunity for the company to expand its formulation business into the Panamanian market, enhancing its internationalization strategy [1] - However, there is uncertainty regarding the sales performance in this new market [1]